EDP-235 is under clinical development by Enanta Pharmaceuticals and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EDP-235’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EDP-235 overview
EDP-235 is under development for the treatment of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is administered through oral route of administration as a capsule. It acts by targeting 3CL-protease (3CLp).
Enanta Pharmaceuticals overview
Enanta Pharmaceuticals (Enanta) is a clinical-stage biotechnology company that develops small molecule drugs for viral and immune infections. The company’s pipeline products include glecaprevir, a protease inhibitor that targets hepatitis C virus (HCV); EDP-514, a core inhibitor that treats hepatitis B virus (HBV); zelicapavir (EDP-938), a N-protein inhibitor for the respiratory syncytial virus (RSV); EDP-323 and EDP-235, are L-protein inhibitor and 3CL protease inhibitors that target respiratory syncytial virus and COVID-19. It works in partnership with the National Institute of Allergy and Infectious Diseases, AbbVie Inc, Novartis, and Shionogi Inc to discover protease inhibitor compounds. Enanta is headquartered in Watertown, Massachusetts, the US.
For a complete picture of EDP-235’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
